Zevalin Post-marketing Surveillance in Japan
NCT01448928
·
clinicaltrials.gov ↗
COMPLETED
Status
400
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-Hodgkin's Lymphoma (NHL)
Interventions
DRUG:
[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)
Sponsor
Spectrum Pharmaceuticals, Inc
Collaborators
[object Object]